Blanket Purchase Agreement V797D30042-36E79718A0010

Prolacta Bioscience, Inc. was awarded a single award blanket purchase agreement by the Department of the Army Medical Command to provide human breastmilk fortifiers and related products. The BPA has a potential value of $2.5 million and period of performance from October 2017 through September 2022. Prolacta Bioscience is a manufacturer of goods specializing in neonatal nutrition products derived from human breastmilk. Under the BPA, Prolacta Bioscience has received multiple firm fixed price...

The Blanket Purchase Agreement was awarded by the Department of Veterans Affairs National Acquisition Center to Bio Products Laboratory LIMITED for the procurement of albumin products. The single award BPA has a potential value of $37,811.50 for a base year with four option years and aims to procure albumin products through March 31, 2022 under Federal Supply Schedule 61-IB for Pharmaceuticals and Drugs. The BPA was awarded on April 24, 2021 without a set-aside designation to Bio Products...

The National Acquisition Center, a civilian agency of the Department of Veterans Affairs (VA), has awarded a single-award Blanket Purchase Agreement (BPA) to Bio Products Laboratory LIMITED, a for-profit manufacturer of pharmaceutical goods. The BPA, valued at up to $1,125,000 over a base year with four one-year option periods through April 2026, is for the procurement of ALBUMINEX albumin products to be delivered to VA medical facilities nationwide. This BPA is established under the VA's...

This Blanket Purchase Agreement (BPA) was awarded by the National Acquisition Center, a civilian federal agency, to Adaptimmune LLC, a foreign-owned for-profit manufacturer. The BPA has a ceiling value of $5,525,200.00 and a period of performance ending on June 10, 2026. The BPA is for the procurement of TECELRA products and services. While the specific details of the contracted items are not provided, BPAs are typically used to establish a simplified method of filling anticipated repetitive...

This Blanket Purchase Agreement (BPA) was awarded by the National Acquisition Center, a civilian federal agency, to PTC Therapeutics, Inc. as the prime contractor. The BPA, valued at a ceiling of $12,500.00, is for the procurement of EMFLAZA, a medication. The BPA was awarded on March 9, 2024, with a period of performance ending on March 14, 2026. The contract was a single award, with no set-aside used. As a BPA, this contract provides a streamlined mechanism for the agency to order and...

The Blanket Purchase Agreement was awarded as a single award by the Department of Veterans Affairs National Acquisition Center to Aimmune Therapeutics, Inc. The potential value of the BPA is $14 million. The BPA is for the procurement of Palforzia, which is intended to reduce the frequency and severity of allergic reactions to peanuts in patients aged 4 through 17 years. No set-aside was used in the awarding of this BPA. The period of performance for orders placed against the BPA extends through...

This Blanket Purchase Agreement (BPA) was awarded by the National Acquisition Center, a civilian federal agency, to Adma Biologics, Inc., a for-profit pharmaceutical company. The BPA has a ceiling value of $49,000,000 and runs through July 31, 2026. It covers the procurement of two plasma-derived pharmaceutical products: ASCENIV and BIVIGAM. Adma Biologics, which specializes in hematology-related products, also holds two Federal Supply Schedule (FSS) contracts with the Department of Veterans...

The Defense Health Agency awarded a blanket purchase agreement to Progenics Pharmaceuticals Inc. to procure PILARIFY (PIFLUFOLASTAT F-18) injection, an imaging agent used in positron emission tomography scans to aid in the detection and localization of prostate cancer. The BPA has a potential value of $250,000 and period of performance through April 2027. Multiple firm fixed price call contracts have been placed against the BPA at various medical treatment facilities for delivery of PILARIFY...

This Blanket Purchase Agreement (BPA) was awarded by the National Acquisition Center, a civilian agency, to Sanofi-Aventis U.S. LLC, a foreign-owned for-profit organization, with no set-aside used. The single-award BPA has a ceiling value of $5,000,000.00 and a period of performance from July 1, 2024, to June 30, 2026. The BPA is for the procurement of TZIELD, a pharmaceutical product. As a BPA, this contract provides a streamlined mechanism for the agency to order and obtain TZIELD from the...

This Blanket Purchase Agreement (BPA) was awarded by the Department of Health and Human Services (HHS), National Institutes of Health (NIH), to MBL International Corporation, a for-profit manufacturer of goods. The BPA covers the procurement of blood/blood products, biological materials, and chemicals. The BPA has no set-aside and was originally awarded on July 11, 2002, with an open-ended potential value. Under this BPA, three task orders have been issued to date. The first, awarded on December...